136 related articles for article (PubMed ID: 11032928)
21. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.
Ritter R; Hennenlotter J; Kühs U; Hofmann U; Aufderklamm S; Blutbacher P; Deja A; Hohneder A; Gerber V; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
Urol Oncol; 2014 Apr; 32(3):337-44. PubMed ID: 24332643
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
23. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
25. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
26. Urine laminin P1 assessment discriminates between invasive and noninvasive urothelial cell carcinoma of the bladder.
Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW
Urol Int; 1993; 51(4):204-8. PubMed ID: 8266611
[TBL] [Abstract][Full Text] [Related]
27. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
28. Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.
Ecke TH; Arndt C; Stephan C; Hallmann S; Lux O; Otto T; Ruttloff J; Gerullis H
Anticancer Res; 2015 May; 35(5):2651-5. PubMed ID: 25964541
[TBL] [Abstract][Full Text] [Related]
29. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?
Richter P; Tost M; Franz M; Altendorf-Hofmann A; Junker K; Borsi L; Neri D; Kosmehl H; Wunderlich H; Berndt A
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1351-8. PubMed ID: 19326143
[TBL] [Abstract][Full Text] [Related]
30. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
[TBL] [Abstract][Full Text] [Related]
31. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
32. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?
Gecks T; Junker K; Franz M; Richter P; Walther M; Voigt A; Neri D; Kosmehl H; Wunderlich H; Kiehntopf M; Berndt A
Clin Chim Acta; 2011 Oct; 412(21-22):1931-6. PubMed ID: 21763295
[TBL] [Abstract][Full Text] [Related]
33. Cytokeratin shedding in urine as a biological marker for bladder cancer: monoclonal antibody-based evaluation.
Helmy H; Seddek MN; Basta MT; Shaaban A; el-Baz M; el-Masry S; al-Hilaly ES; Ghoneim MA
Br J Urol; 1991 Sep; 68(3):248-53. PubMed ID: 1717095
[TBL] [Abstract][Full Text] [Related]
34. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
35. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
36. UBC®Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population.
Zang Z; Kesavan NR; Esuvaranathan K
Urol Int; 2023; 107(1):29-34. PubMed ID: 36273445
[TBL] [Abstract][Full Text] [Related]
37. BLCA-4 and UBC combined detection for early diagnosis of bladder cancer.
Cui L; Sun MM; Zhao ZH; Yang JP; Zheng YP; He LL; Chen KS; Fan QX
J Biol Regul Homeost Agents; 2016; 30(2):485-90. PubMed ID: 27358136
[TBL] [Abstract][Full Text] [Related]
38. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a New Survivin ELISA and UBC
Gleichenhagen J; Arndt C; Casjens S; Meinig C; Gerullis H; Raiko I; Brüning T; Ecke T; Johnen G
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29324722
[TBL] [Abstract][Full Text] [Related]
40. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]